A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Belrestotug (Primary) ; Cobolimab (Primary) ; Dostarlimab (Primary) ; Nelistotug (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 14 Mar 2025 Planned End Date changed from 3 Sep 2025 to 31 Dec 2025.
- 14 Mar 2025 Planned primary completion date changed from 3 Sep 2025 to 31 Dec 2025.
- 14 Mar 2025 Status changed from recruiting to active, no longer recruiting.